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ABSTRACT
Introduction: Allergic rhinitis (AR) is one of the
most common chronic respiratory diseases
observed in the pediatric population,
producing a significant morbidity, and an
economic burden due to direct medical costs
and indirect costs. Despite the high prevalence
of AR in children and the importance of the use
of topical intranasal corticosteroids for its
treatment, comparative analyses of alternative
treatments in pediatric patients, in terms of
both cost and effectiveness are lacking.
Methods: A decision-analysis model was
developed to estimate the cost-effectiveness of
mometasone furoate nasal spray (MFNS)
compared to beclomethasone dipropionate
nasal spray (BDNS) for treating pediatric
patients with AR over a 12-month period.
Effectiveness parameters were obtained from a
published study in which authors performed a
systematic review of the literature. Cost data
were obtained from a hospital´s bills and from
the national manual of drug prices. The study
assumed the perspective of the national
healthcare in Colombia. The outcomes were
three effectiveness measures summarized in a
therapeutic index (TIX).
Results: For the base-case analysis, the model
showed that compared to BDNS, therapy with
MFNS was associated with lower costs
(US$229.78 vs. 289.74 average cost per patient
over 12 months) and a greater improvement in
TIX score (0.9724 vs. 0.8712 score points on
average per patient over 12 months), thus
leading to dominance.
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Conclusion: The present analysis shows that in
Colombia, compared with BDNS, therapy with
MFNS for treating pediatric patients with AR is a
dominant strategy because it showed a greater
improvement in a TIX reflecting both efficacy
and safety, at lower total treatment costs.
Keywords: Allergic rhinitis; Children; Cost-
effectiveness; Intranasal corticosteroids;
Treatment outcome; Health care costs
INTRODUCTION
Allergic rhinitis (AR) is a global health problem
and one of the most common chronic
respiratory diseases observed in the pediatric
and adult population, with an estimated
prevalence of approximately 20–40 million in
the US population [1]. In Colombia a prevalence
of AR symptoms has been reported ranging
from 29.5% to 33.9% for the whole population,
and from 25.9% to 53.8% for the pediatric
population [2, 3]. Despite the fact that AR is not
directly associated with a high rate of mortality
or a high rate of hospitalization, the disease
produces a significant morbidity. This
condition has a major impact on the quality
of life, sleeping habits, academic performance,
daily activities, and concentration of sufferers
[4]. Furthermore, in pediatric patients,
improperly managed AR may contribute to the
worsening of comorbid conditions, including
asthma, rhino sinusitis, and otitis media [5].
The aforementioned factors lead to significant
economic burden due to direct medical costs
such as prescriptions and ambulatory care visits,
and indirect costs such as absenteeism from
school and work [6, 7].
Although there are many therapeutic
options for the treatment of AR, topical
intranasal corticosteroids (INS) are considered
the most effective medication class for
controlling symptoms of the disease [1]. INS
have shown to reduce nasal congestion,
rhinorrhea, sneezing, pruritus, and can also
relieve ocular symptoms [8]. In Colombia,
beclomethasone dipropionate nasal spray
(BDNS) and mometasone furoate nasal spray
(MFNS) are the two most commonly prescribed
and the leading INS by market share in the
country [9]; however, currently BDNS is the
only INS included in Colombia’s compulsory
health insurance plan.
Despite the high prevalence of AR in
children and the importance of the use of INS
for the treatment of AR, comparative analyses of
alternative treatments in pediatric patients, in
terms of both cost and effectiveness are lacking.
These comparative analyses are important
because differences in cost of acquisition,
efficacy, side effects, and therapeutic
adherence between alternative treatments for
AR could have a considerable impact on the
control and in the tremendous economic
burden of the disease. Cost-effectiveness
analysis (CEA) provides a tool with which to
incorporate both cost and effectiveness of
alternative treatments.
The aim of the present study was to compare
the cost-effectiveness of MFNS compared to
BDNS for treating pediatric patients with AR in
Colombia.
METHODS
Structure of the Model
A decision-analysis model was developed to
estimate the cost-effectiveness of MFNS
compared to BDNS for treating pediatric
patients with AR. Although combination
therapy with INS and antihistamines is
occasionally used to treat the symptoms of AR,
patients included in the model were only those
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treated with a single prescription therapy of INS
for symptom relief of AR. We chose BDNS
because it is currently the only INS included
in Colombia’s compulsory health insurance
plan. Additionally, MFNS, marketed by Merck
Sharp & Dohme (MSD) under the brand-name
Nasonex, is—along with BDNS—the most
commonly prescribed and the leading INS by
market share in the country. For each of the two
comparators, the model starts with a patient
aged between 2 and 18 years who presents with
AR and there is a probability (probability node)
of improvement of symptoms. For patients
whose symptoms improved, the model
incorporates the probability that this
improvement of symptoms has been due to
improvement of nasal symptoms, ocular
symptoms, or global assessment. Thereafter,
the model incorporates the probability of
treatment-related adverse events, and if these
adverse events comprised epistaxis or not. For
patients whose symptoms do not improve, the
model incorporates the option (decision node)
to continue treatment with a more effective INS
or to send the patient for additional diagnostic
and therapeutic procedures (Fig. 1). The model
assumed that there would be complete
compliance with either treatment measure
throughout the entire year of follow-up.
Although as determined by the natural history
of AR it could be more appropriate to use a
Markov model instead of a simple decision tree,
we used the latter because we considered that
using a simple decision tree it was possible to
include the most important clinical events
resulting from each of the two therapeutic
options without unrealistic simplifying
assumptions.
The model compared the one-year direct
medical costs (including medical consultations,
imagenology studies, and other diagnostic and
therapeutic procedures for patients with no
improvement of symptoms on therapy with
INS, or for patients who presented treatment-
Fig. 1 Diagram of cost-effectiveness model for each
treatment option. Asterisk For patients whose symptoms
do not improve and the decision is to continue treatment
with a more effective topical intranasal corticosteroid, the
model follows as it is depicted for beclomethasone
dipropionate nasal spray
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related adverse events such as epistaxis or
increased intraocular pressure) and disease
outcomes from the perspective of the national
healthcare system in Colombia.
Three effectiveness measures were chosen as
the basis for this model: a composite total nasal
symptom score (TNSS), defined as the average
effect size for each of the two comparators for
nasal symptoms, a composite total ocular
symptom score (TOSS), defined as the average
size for ocular symptoms, and a patient (or
physician) global assessment (PGA).
Sources of Data
Disease Outcomes and Clinical Parameters
Assumptions regarding the probability of
improvement of nasal symptoms, ocular
symptoms and global assessment, the
probability of treatment-related adverse events,
and if these adverse events comprised epistaxis
or not, were derived from the literature.
Specifically, we identified a published study in
which authors performed a systematic review of
the literature (1966 to June 2009) to identify
potentially relevant studies on efficacy and
safety of several INS, including BDNS and
MFNS [10]. In this study, the authors aimed to
develop a therapeutic index (TIX) reflecting
both efficacy and safety of these substances in a
combined assessment. To develop this TIX, the
authors performed meta-analyses for each
single INS and for the parameters TNSS, TOSS,
PGA, and epistaxis. The meta-analyses results
for the different INS and the parameter TNSS,
TOSS, PGA, and epistaxis were ordered and then
categorized into scores from 0 to 3 using
quartiles. The scores of long-term side effects
and systemic ocular side effects were based on
the highest level of evidence reflected by the
study type of available studies and its results.
The score points for the three efficacies and the
three safety parameters were then summarized
for each INS resulting in individual summation
scores of ‘sum efficacy’ (ES) and ‘sum side
effects’ (AES), which could range between a
minimum of 0 and maximum of 9 points. A
high ES would indicate a high efficacy and a
high AES a high potential for side effects. The
final TIX score was then calculated as the ratio
of ES and AES with a theoretical maximum of 9
points indicating an optimal balance of a
maximum efficacy and a minor potential of
side effects [10]. Table 1 presents the
summation scores of each parameter as well as
the final TIX score for BDNS, MFNS, and for
budesonide aqueous nasal spray (BANS). We
included the data of BANS because, for patients
whose symptoms do not improve, the model
incorporates the possibility (decision node) to
continue treatment with a more effective INS.
Based on the summation scores of ES, the model
assumed that MFNS is the next most effective
Table 1 TIX scores for each parameter, subscales and ﬁnal
ratio by topical intranasal corticosteroid
Parameter BDNS MFNS BANS
TNSS 2 3 2
TOSS 1 2 3
PGA 1 2 3
ES 4 7 8
Epistaxis 2 1 2
Long-term side effect 3 0 2
Systemic ocular side effects 2 0 0
AES 7 1 4
TIX (ES/AES) 0.57 7 2
Table modiﬁed from [10]
AES sum side effects, BANS budesonide aqueous nasal
spray, BDNS beclomethasone dipropionate nasal spray, ES
sum efﬁcacy, MFNS mometasone furoate spray nasal, TIX
therapeutic index, TNSS total nasal symptom score, TOSS
total ocular symptom score, PGA patient (or physicians)
global assessment
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INS for BDNS, and BANS is the next most
effective INS for MFNS (Table 1). Probabilities of
efficacy parameters were obtained based on the
efficacy scores summarized in the TIX. The
probability of improvement of symptoms with
each one of the INS was calculated as the
proportion of the maximum score for efficacy
parameters with respect to the maximum
possible score for efficacy parameters, and the
probability of side effects with each one of the
INS was calculated as the proportion of the
maximum score for side effects parameters with
respect to the maximum possible score for side
effects parameters. Likewise, probabilities of
efficacy parameters for TNSS, TOSS, and PGA
were calculated as the proportion of the TIX
scores for each parameter with respect to the
maximum score for efficacy parameters, and
probability of epistaxis was calculated as the
proportion of the TIX score for epistaxis with
respect to the maximum score for side effects.
Resource Utilization and Costs
As mentioned, the CEA was conducted from the
perspective of the national healthcare system in
Colombia and hence only direct costs were
included in the analysis. In particular, the costs
of medical consultations (pediatrician,
otolaryngologists, allergologist, endocrinologist,
and ophthalmologist), imagenologic studies
(computed tomography scan of the paranasal
sinuses, radiography of the paranasal sinuses,
and lateral airway radiography to determine the
adenoid size), as well as additional diagnostic and
therapeutic procedures for patients with no
improvement of symptoms on therapy with INS
(Immunoglobulin E, skin prick testing,
immunotherapy, impedance audiometry,
endoscopic nasopharyngoscopy, adenoidectomy,
septoplasty, tympanostomy tube placement, and
turbinoplasty), were taken account of. Additional
resources used for treatment-related adverse
events (cauterization, anterior nasal packing,
analgesic, topical antibiotics, and intraocular
pressure measurement) were also included. All
costs gathered were as close to reimbursement or
true costs as possible.
Calculation of the daily therapy with INS was
based on the estimated average daily dose
appropriate for treating pediatric patients with
AR, according to current international AR
guidelines [11, 12], and the relative use of
available concentrations for each medication
according to current market research. The
starting doses used in the present model were 2
sprays per nostril 2 times a day (400 lg total dose)
for BDNS, 1 spray per nostril every day (100 lg
total dose) for MFNS, and 1 spray per nostril 2
times a day (128 lg total dose) for BANS.
To determine the utilization rates of health
resources and events for patients with no
improvement of symptoms on therapy with
INS and for patients with treatment-related
adverse events, we performed a review of the
literature, a consensus of experts consisting of a
panel of three local pediatric otolaryngologists
using the Delphi technique [13], and verified
the results with a review of randomly selected
medical records of 37 pediatric patients
attended in the Fundacion Hospital La
Misericordia with a principal diagnosis of AR
(ICD-10 codes J30.1, J30.2, J30.3, and J30.4)
between January 1 and December 31, 2013. The
Fundacion Hospital La Misericordia is a referral
hospital located in the metropolitan area of
Bogota that receives patients from the most
representative medical insurance companies in
the city. The data number collected on health
utilization were: the number of medical
consultations per year (pediatrician,
otolaryngologists, allergologist,
endocrinologist, and ophthalmologist), the
percent of patients requiring imagenologic
studies (computed tomography scan of the
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paranasal sinuses, radiography of the paranasal
sinuses, and lateral airway radiography to
determine the adenoid size), the percent of
patients requiring additional diagnostic and
therapeutic procedures (immunoglobulin E,
skin prick testing, immunotherapy, impedance
audiometry, endoscopic nasopharyngoscopy,
adenoidectomy, septoplasty, tympanostomy
tube placement, and turbinoplasty), and the
percent of patients requiring additional
resources used for treatment-related adverse
events (cauterization, anterior nasal packing,
analgesic, and topical antibiotics).
Unit costs of all medications were taken from
the Drug Price Information System (SISMED,
2013) [9], an official database provided by the
Colombian Ministry of Health and Social
Protection, which represents an important
primary source of medication prices in the
country. Costs of INS for the model were
calculated as the expected days of therapy per
year multiplied by their daily cost, dosed at
their recommended starting doses.
Costs were calculated in Colombian Pesos
(COP) and converted to Dollars (US$) based on
the average exchange rate for 2013 (1
US$ = 1868.90 COP) [14]. All the costs were
adjusted to 2013 COPs before converting them
to US$s. Given that the model duration was
1 year, costs and effects were not discounted.
The study protocol was approved by the local
ethics board. The analysis in this article is based
on previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Sensitivity Analyses
A series of one-way, two-way, and multi-way
sensitivity analyses (using a tornado diagram)
and the effect of alternative model
specifications were examined. Data ranges in
sensitivity analyses were derived from various
sources: for unit costs of resources, data ranges
were plus or minus 25% of the base value,
because it was considered that this range
represents a reasonable one for these unit
costs. For the rates of resource utilization for
patients with no improvement of AR symptoms
and for patients with treatment-related adverse
events with INS, data ranges in sensitivity
analyses were derived from 95% confidence
intervals (CI) from the review of the literature,
the values reported in the consensus of experts,
and the review of the medical records. Finally,
for unit costs of all medications, data ranges in
sensitivity analyses were established from the
low and high values reported from SISMED (an
official database provided by the Colombian
Ministry of Health). In addition, a probabilistic
sensitivity analysis using second-order Monte
Carlo simulation was conducted to account for
the uncertainties associated with the model
parameters using a cohort of 10,000 trial
simulations for both alternatives. This
probabilistic sensitivity analysis allowed us to
generate 95% uncertainty intervals (UI) around
costs and effects. These were presented
graphically on a cost-effectiveness plane to
show the estimated joint distribution of
incremental costs against incremental effects
and evaluated using net benefit analysis [15].
Subsequently, a cost-effectiveness acceptability
curve (CEAC) was derived from these data [16]
to identify which alternative would be the most
cost-effective at various thresholds of
willingness-to-pay (WTP) for TIX score point.
All analyses were performed with software
(TreeAgePro 2012, TreeAge Software,
Williamstown, MA, USA).
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RESULTS
Base-Case Analysis
With respect to single INS the value of both the
unit cost and the cost of daily treatment with
BDNS were lower than those costs of MFNS,
whereas the efficacy of MFNS was greater than
the efficacy of BDNS. Likewise, the potential for
side effects was higher for BDNS compared to
MFNS (Table 2).
While the anterior nasal packing was the
resource with the greatest unit cost for patients
with drug-related adverse events with INS use,
septoplasty was the resource with the greatest
unit cost for patients whose symptoms did not
improve with the use of INS (Table 3). Likewise,
while cauterization was the resource with the
greatest rate of utilization for patients with
drug-related adverse events with INS,
immunotherapy, and endoscopic
nasopharyngoscopy were the resources with
the greatest rate of utilization for patients
whose symptoms did not improve with the
use of INS (Table 4).
Using the base-case assumptions, the model
showed that compared to BDNS, therapy with
MFNS was associated with lower costs
(US$229.78 vs. US$289.74 average cost per
patient over 12 months) and a greater
improvement in TIX score (0.9724 vs. 0.8712
score points on average per patient over
12 months), thus leading to dominance. A
position of dominance negates the need to
calculate an incremental cost-effectiveness ratio
(Table 5).
Sensitivity Analyses
One-way, two-way, and multi-way
deterministic sensitivity analyses (using a
tornado diagram) showed that the cost of
pediatric consultation and the cost of MFNS
have the highest impact on the model outcome.
However, MFNS was the dominant strategy over
all the ranges of the cost of pediatric
consultations and the cost of MFNS analyzed.
Table 2 Probability parameters (baseline value, low value

















Side effects 77.0 69.0 85.0
Epistaxis 28.0 25.0 31.0










Side effects 11.0 10.0 12.0
Epistaxis 100.0 0.0 0.0










Side effects 44.0 40.0 48.0
Epistaxis 44.0 40.0 48.0
Probability calculations based on three efﬁcacy and three
safety parameters summarized in a therapeutic index [10]
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Parameter distributions used in the probabilistic
sensitivity analysis are presented in Table 6. The
results of the probabilistic sensitivity analysis
are graphically represented as a scatter plot in
Fig. 2. This scatter plot shows that MFNS tends
to be associated with lower costs and a greater
improvement in TIX score. Based on the results
from this simulation, the 95% UI for cost per
patient treated with MFNS and BDNS were
US$186.87 to US$282.22 and US$238.20 to
Table 3 Unit costs of resources for pediatric allergic rhinitis (US$, 2013)
Cost item Baseline value Low value High value
Drug-related adverse events with topical intranasal corticosteroids
Cauterization 17.81 13.36 22.26
Anterior nasal packing 28.56 21.42 35.70
Topical antibiotic 3.21 2.41 4.01
Analgesic 3.47 2.60 4.33
Seric cortisol 26.75 20.06 33.44
Diagnostic and/or therapeutic proceduresa
Immunoglobulin E 32.41 24.30 40.51
Skin prick testing 80.26 60.20 100.33
Immunotherapyb 62.02 46.51 77.52
Lateral airway radiography 18.43 13.82 23.04
CT scan of the paranasal sinuses 193.61 145.21 242.01
Impedance audiometry 6.02 4.51 7.52
Endoscopic nasopharyngoscopy 474.73 356.05 593.41
Tympanostomy tube placement 200.12 150.09 250.15
Turbinoplasty 433.26 324.95 541.58
Adenoidectomy 333.47 250.10 416.84
Septoplasty 824.84 618.63 1,031.05
Medical consultationsc 24.08 18.06 30.10
Topical intranasal corticosteroids
Beclomethasone dipropionate nasal sprayd 2.34 2.29 2.76
Mometasone furoate nasal spraye 13.29 9.13 14.25
Budesonide aquous nasal sprayf 43.62 37.59 46.22
CT computed tomography
a Diagnostic and/or therapeutic procedures for patients whose symptoms did not improve
b Complete monthly cost of immunotherapy
c Unit cost of medical consultations (pediatrician, otolaryngologist, allergologist, endocrinologist, and ophthalmologist)
d Unit cost of beclomethasone dipropionate nasal spray, 200 doses
e Unit cost of mometasone furoate nasal spray, 140 doses
f Unit cost of budesonide aqueous nasal spray, 120 doses
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Table 4 Rates of resource utilization for patients with no improvement of allergic rhinitis symptoms and for patients with
treatment-related adverse events with topical INS
Resources Rate of resource utilization Range
Patients with no improvement of allergic rhinitis symptoms
Immunoglobulin Ea 3.7% 1.7–5.7%
Skin prick testinga 46.7% 40.0–51.7%
Immunotherapya 50.0% 38.3–58.3%
Lateral airway radiographya 34.4% 31.0–37.3%
CT scan of the paranasal sinusesa 41.7% 37.3–46.0%
Impedance audiometrya 3.3% 1.7–6.7%
Endoscopic nasopharyngoscopya 50.0% 44.0–55.0%




Pediatric consultationb 4.3 4.0–5.0
Otolaryngologist consultationb 4.3 4.0–5.0
Allergologist consultationb 3.0 2.0–4.0
Patients with treatment-related adverse events with INS
Epistaxis
Cauterizationa 4.7% 2.3–9.7%
Anterior nasal packinga 0.7% 0.3–2.7%
Topical antibiotica 3.7% 2–7.3%
Analgesica 1.3% 0.3–3%
Pediatric consultationb 3.6 3.0–4.0
Otolaryngologist consultationb 2.6 2.0–3.0
Treatment-related adverse event other than epistaxis
Pediatric consultationb 3.0 2.0–4.0
Endocrinologic consultationb 2.0 1.0–3.0
Ophthalmologist consultationb 2.0 1.0–3.0
Seric cortisol measurementc 2.0 1.0–3.0
CT computed tomography, INS intranasal corticosteroids
a Average percentage of patients that require the diagnostic/therapeutic procedure
b Average number of consultations per year
c Average number of measurements per year
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US$348.60, respectively. Likewise, these 95% UI
for TIX scores were 0.9464–0.9897 and
0.8240–0.9131 score points, respectively. In
97.6% of the iterations, MFNS was associated
with a greater improvement in TIX score and
lower costs compared to therapy with BDNS.
The CEAC shows that the probability that daily
therapy provides a cost-effective use of
resources compared to intermittent therapy
exceeds 99% for all WTP thresholds (Fig. 3).
DISCUSSION
The present study shows that compared to
BDNS, therapy with MFNS for treating
pediatric patients with AR is a dominant
strategy because it showed a greater
improvement in a TIX reflecting both efficacy
and safety, at lower total treatment costs.
Although the variables that exhibited a
significant effect on these results were the cost
of pediatric consultation and the cost of MFNS,
therapy with MFNS was the dominant strategy
over all the ranges of the cost of pediatric
consultations and the cost of MFNS analyzed. It
is worth mentioning that, to the best of our
knowledge, this is the first study to compare
MFNS and BDNS for treating pediatric patients
with AR, in terms of both cost and effectiveness.
The findings of the present study support the
use of MFNS as the most efficient therapy in
pediatric patients with AR diagnosis in
Colombia and probably in other similar low-
and middle-income countries (LMIC), at least
when it is compared exclusively with BDNS.
These results are important because although
MFNS has a higher cost of acquisition relative to
BDNS, it is associated with lower total treatment
costs and better health outcomes in pediatric
patients with AR. These findings should help to
support the daily clinical decision-making
process of choosing between a range of
options for these patients. When choosing the
most efficient therapy for treating pediatric AR,
it is possible to impact on the significant
morbidity and economic burden associated
with the disease. Although traditionally it has
been assumed that safety and efficacy is proven
for all available INS, and that they are all
equally effective in controlling symptoms of
AR, our results do not support this previous
assumption. Although there is no single trial
which directly compares all the available INS,
and our model did not include all INS currently
licensed in Colombia for use in children with
AR, the systematic aggregation and analysis of
both efficacy and cost data in our study suggests
that the choice among the different treatments
available can have a great impact on the health
outcomes and costs of the disease.
Our results agree with those published by
Portnoy et al. [17] who found, using an
evidence-based medicine approach to assess
efficacy and safety in a combined parameter










MFNS 229.78 – 0.9724 – 236.31
Absolutely
dominated
BDNS 289.74 59.96 0.8712 -0.1012 332.58
BDNS beclomethasone dipropionate nasal spray, MFNS mometasone furoate nasal spray, TIX therapeutic index
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Table 6 Parameter distributions used in the probabilistic sensitivity analysis
Probability distribution Distribution parameters Distribution parameters
Beta distribution Alpha Beta




















Gamma distribution Alpha Lambda
Cost of cauterization 64.072 3.597
Cost of anterior nasal packing 64.000 2.241
Cost of topical antibiotic 64.400 20.062
Cost of analgesic 64.370 18.550
Cost of seric cortisol 63.952 2.390
Cost of immunoglobulin E 64.039 1.975
Cost of skin prick testing 64.000 0.797
Cost of immunotherapy 64.000 1.031
Cost of lateral airway radiography 63.930 3.468
Cost of CT scan of the paranasal sinuses 64.006 0.330
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comparing different INS, the best safety/efficacy
ratio for MFNS. This study, however, considered
only one parameter each for safety and efficacy,
did not include BDNS in the analyses, and did
not incorporate costs of alternative treatments.
Likewise, in agreement with our findings, there
are reports that support the difference in the
proportion of costs for a daily dose of BDNS
Fig. 2 Scatter plot of each iteration’s cost and effectiveness
values for each strategy in pediatric allergic rhinitis. The
x-axis shows effectiveness measured as efﬁcacy and safety
parameters summarized in a therapeutic index; the y-axis
shows costs measured in dollars (US$, 2013). Each point
represents one of the 10,000 trial simulations, where each
input was assigned a random value according to its
probability density function
Table 6 continued
Probability distribution Distribution parameters Distribution parameters
Cost of impedance audiometry 64.000 10.631
Cost of endoscopic nasopharyngoscopy 2583.447 5.441
Cost of tympanostomy tube placement 64.000 0.319
Cost of turbinoplasty 64.000 0.147
Cost of adenoidectomy 63.996 0.191
Cost of septoplasty 64.000 0.077
Cost of BDNS 396.603 169.488
Cost of MFNS 107.802 8.111
Cost of BANS 408.761 9.370
BANS budesonide aqueous nasal spray, BDNS beclomethasone dipropionate nasal spray, CT computed tomography,MFNS
mometasone furoate nasal spray
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compared to a daily dose of MFNS [18].
Reissman et al. [19] determined the physician
prescribing patterns of the leading INS from the
National Disease and Therapeutic Index
database in the US, and compared economic
differences resulting from these prescribing
behaviors. The authors of this study concluded
that BANS offers more days of treatment at a
lower cost per day than other leading INS.
However, unlike our study, this study did not
include BDNS in the analyses, did not consider
parameters for safety or efficacy of alternative
treatments, and did not take into account that
starting dosage of INS is different in pediatric
patients compared to adult patients. For the
reasons mentioned above, it is difficult to more
accurately compare our results with those
published in the literature.
Our model also has some limitations. First,
the base-case analysis was run for 12 months
instead of a complete lifetime. However, we
judged a 12-month period to be enough for
determining the major health and economic
consequences of the use of INS in pediatric AR.
Second, we did not take into account the effect
of incomplete and failing adherence to therapy
that typically occurs when treating chronic
diseases such as AR. However, this is a
conservative approach, since fewer prescribed
daily doses are likely an important component
of adherence to AR therapy and improved long-
term outcomes [20], and there are differences in
Fig. 3 Cost-effectiveness acceptability curve with MFNS
versus BDNS for pediatric allergic rhinitis. The cost-
effectiveness acceptability curve shows the probability of
MFNS being cost-effective compared to BDNS over a wide
range of WTP thresholds. This probability exceeds 99% for
all WTP thresholds. BDNS beclomethasone dipropionate
nasal spray, MFNS mometasone furoate nasal spray, WTP
willingness-to-pay
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dosing regimens between MFNS and BDNS
(once daily vs. twice daily, respectively). In
fact, published studies have reported a
significantly greater level of adherence in
patients with AR treated with MFNS compared
to those treated with BDNS [21]. Third,
although we assumed that differences in the
results of the efficacy and safety parameters
summarized in the TIX have a similar clinical
significance, it’s unclear whether this
assumption is actually true. This is mainly
because there has not been a direct
comparison of all INS with regard to the
efficacy and safety outcomes analyzed in the
present study. Fourth, assumptions regarding
the probability of improvement of nasal
symptoms, ocular symptoms and global
assessment, the probability of treatment-
related adverse events, and if these adverse
events comprised epistaxis or not, were
derived from a published study in which
authors only included studies up to 2009, so it
is probable that this study does not reflect the
current state of scientific knowledge. However,
in this study, authors performed a systematic
review of the literature and developed a TIX
reflecting both efficacy and safety of these
substances in a combined assessment.
Although this fact increase the confidence in
obtaining unbiased results, it would be
important that future studies determine the
cost-effectiveness of different INS based on
more recent literature. Finally, cost data were
obtained from a single clinical center and may
not be representative of the whole country.
However, these data were obtained from a
pediatric clinic that receives patients from the
most important and representative medical
insurance companies in the city. Moreover,
costs were subject to wide sensitivity analyses.
CONCLUSIONS
The present analysis shows that in Colombia,
compared with BDNS, therapy with MFNS for
treating pediatric patients with AR is a
dominant strategy because it showed a greater
improvement in a TIX reflecting both efficacy
and safety, at lower total treatment costs.
Although it is difficult to assess the clinical
relevance of differences in efficacy and safety
parameters summarized in the TIX, these results
may help to support clinical decision making
until more robust evidence is available.
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